Biotransformation

• 

  Subject Areas on Research

  • 2,4,6-Tribromophenol Disposition and Kinetics in Rodents: Effects of Dose, Route, Sex, and Species. 
  • A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. 
  • A two one-sided tests procedure for assessment of individual bioequivalence. 
  • ATP receptor activation potentiates a voltage-dependent Ca channel in hippocampal neurons. 
  • Absence of metabolite formation during nitroglycerin-induced relaxation of isolated blood vessels. 
  • Activation of cyclophosphamide for in vitro testing of cell sensitivity. 
  • Adrenocorticotropic hormone biotransformation, clearance, and catabolism. 
  • Advances in enzymology and related areas of molecular biology. Preface. 
  • Aging and cancer. 
  • Analysis of alkylphenol ethoxylate metabolites in the aquatic environment using liquid chromatography-electrospray mass spectrometry. 
  • Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. 
  • Bacterial conversion of folinic acid is required for antifolate resistance. 
  • Bactericidal agents generated by the peroxidase-catalyzed oxidation of para-hydroquinones. 
  • Beta-arrestins and cell signaling. 
  • Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. 
  • Biotransformation of HBCD in biological systems can confound temporal-trend studies. 
  • Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism. 
  • Biotransformation of sevoflurane. 
  • Bis(alkylamino)anthracenedione antineoplastic agent metabolic activation by NADPH-cytochrome P-450 reductase and NADH dehydrogenase: diminished activity relative to anthracyclines. 
  • Caenorhabditis elegans generates biologically relevant levels of genotoxic metabolites from aflatoxin B1 but not benzo[a]pyrene in vivo. 
  • Carcinogenicity of a nephrotoxic metabolite of the "nongenotoxic" carcinogen hydroquinone. 
  • Chloroperoxidase-catalyzed halogenation of antipyrine, a drug substrate of liver microsomal cytochrome P-450. 
  • Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. 
  • Comparison of human and rat hepatocyte metabolism and mutagenic activation of 2-acetylaminofluorene. 
  • Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. 
  • Cytochrome P-450- and glutathione-associated enzyme activities in freshly isolated enriched lung cell fractions from beta-naphthoflavone-treated male F344 rats. 
  • Debromination of polybrominated diphenyl ether congeners BDE 99 and BDE 183 in the intestinal tract of the common carp (Cyprinus carpio). 
  • Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. 
  • Dietary accumulation and metabolism of polybrominated diphenyl ethers by juvenile carp (Cyprinus carpio). 
  • Differential metabolism of O-ethyl O-4-nitrophenyl phenylphosphonothioate by rat and chicken hepatic microsomes. 
  • Disposition, pharmacokinetics, and metabolism of a dermal dose of [14C]2,5-hexanedione in hens. 
  • Effect of CYP1A inhibition on the biotransformation of benzo[a]pyrene in two populations of Fundulus heteroclitus with different exposure histories. 
  • Effect of Multi Drug Resistance Protein 4 (MRP4) Inhibition on the Pharmacokinetics and Pharmacodynamics of Ciprofloxacin in Normal and Rats with LPS-Induced Inflammation. 
  • Effect of carbon source addition on toluene biodegradation by an Escherichia coli DH5alpha transconjugant harboring the TOL plasmid. 
  • Effect of hyperthermia on cisplatin pharmacokinetics in normal dogs. 
  • Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. 
  • Ethanol interferes with regeneration-associated changes in biotransforming enzymes: a potential mechanism underlying ethanol's carcinogenicity? 
  • Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. 
  • Gas chromatographic-mass spectrometric analysis of alfentanil metabolites. Application to human liver microsomal alfentanil biotransformation. 
  • Genetic bioaugmentation as an effective method for in situ bioremediation: functionality of catabolic plasmids following conjugal transfers. 
  • Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. 
  • Gossypol: subcellular localization and stimulation of rat liver microsomal oxidases. 
  • Hepatocyte uptake of alpha 1-proteinase inhibitor-trypsin complexes in vitro: evidence for a shared uptake mechanism for proteinase complexes of alpha 1-proteinase inhibitor and antithrombin III. 
  • Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. 
  • Identification of the enzymatic mechanism of nitroglycerin bioactivation. 
  • Identifying genomic and developmental causes of adverse drug reactions in children. 
  • In vitro and in vivo genotoxicity evaluation of hormonal drugs. II. Dexamethasone. 
  • In vitro metabolism and interactions of pyridostigmine bromide, N,N-diethyl-m-toluamide, and permethrin in human plasma and liver microsomal enzymes. 
  • In vitro metabolism of cyclosporine A by human kidney CYP3A5. 
  • In vivo 31P nuclear magnetic resonance studies on the absorption of triphenyl phosphite and tri-o-cresyl phosphate following subcutaneous administration in hens. 
  • In vivo and in vitro debromination of decabromodiphenyl ether (BDE 209) by juvenile rainbow trout and common carp. 
  • Inactivation of metabolic enzymes by photo-treatment with zinc meta N-methylpyridylporphyrin. 
  • Induction of hepatic CYP1A in channel catfish increases binding of 2-aminoanthracene to DNA in vitro and in vivo. 
  • Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. 
  • Inhibition of the gut enzyme intestinal alkaline phosphatase may explain how aspartame promotes glucose intolerance and obesity in mice. 
  • Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care. 
  • Metabolism and toxicity of the new anesthetic agents. 
  • Metabolism of chloroform by cytochrome P450 2E1 is required for induction of toxicity in the liver, kidney, and nose of male mice. 
  • Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. 
  • Microbial hydroxylation and reduction of the diterpene psiadin. 
  • Molecular basis of the biological function of molybdenum: the relationship between sulfite oxidase and the acute toxicity of bisulfite and SO2. 
  • Morphine produces a multiphasic effect on the release of substance P from rat trigeminal nucleus slices by activating different opioid receptor subtypes. 
  • New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 1): Identification of the nephrotoxic metabolic pathway. 
  • New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 2): Identification of nephrotoxic metabolites. 
  • Pathophysiology of the blood-brain barrier: animal models and methods. 
  • Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. 
  • Pharmacokinetics and metabolism of a topically applied dose of O-4-bromo-2,5-dichlorophenyl O-methyl phenylphosphonothioate in hens. 
  • Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. 
  • Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. 
  • Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. 
  • Postoperative oxycodone toxicity in a patient with chronic pain and end-stage renal disease. 
  • Potential role for a guanine nucleotide regulatory protein in chemoattractant receptor mediated polyphosphoinositide metabolism, Ca++ mobilization and cellular responses by leukocytes. 
  • Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: biotinyl-3-[211 At]astatoanilide. 
  • Role of metabolic activation and the TRPA1 receptor in the sensory irritation response to styrene and naphthalene. 
  • Role of mitochondrial aldehyde dehydrogenase in nitroglycerin-induced vasodilation of coronary and systemic vessels: an intact canine model. 
  • Role of the renal cysteine conjugate beta-lyase pathway in inhaled compound A nephrotoxicity in rats. 
  • Sevoflurane, fluoride ion, and renal toxicity. 
  • Similarities and differences in the currents activated by capsaicin, piperine, and zingerone in rat trigeminal ganglion cells. 
  • Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. 
  • Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. 
  • Species-specific differences and structure-activity relationships in the debromination of PBDE congeners in three fish species. 
  • Study of the ability of phenacetin, acetaminophen, and aspirin to induce cytotoxicity, mutation, and morphological transformation in C3H/10T1/2 clone 8 mouse embryo cells. 
  • Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. 
  • The efficacy of the appetite suppressant, diethylpropion, is dependent on both when it is given (day vs. night) and under conditions of high fat dietary restriction. 
  • The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. 
  • The role of pharmacokinetics and metabolism in species sensitivity to neurotoxic agents. 
  • Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target. 
  • Toxicokinetics and metabolism of delayed neurotoxic organophosphorus esters. 
  • Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. 
  • Transformation of pristine and citrate-functionalized CeO2 nanoparticles in a laboratory-scale activated sludge reactor. 
  • Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. 
  • Urinary metabolities of harmine in the rat and their inhibition of monoamine oxidase. 
  • Vaginal deployment and tenofovir delivery by microbicide gels. 
  • Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. 
• 

  Keywords of People

  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases